Welcome to LookChem.com Sign In|Join Free

CAS

  • or

5300-03-8

Post Buying Request

5300-03-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

5300-03-8 Usage

Description

9-CIS-RETINOIC ACID, also known as Alitretinoin, is a vitamin A analog with a chemical structure characterized by 7E,9Z,11E,13E geometry. It is a pale yellow solid and is recognized as an endogenous hormone in mammalian tissues. 9-CIS-RETINOIC ACID is a derivative of 9-cis-retinoic acid and functions as an inhibitor of Cox-2 while also activating RAR α, RAR β, RAR γ, and RXR. It is known for its ability to inhibit cell proliferation, induce cell differentiation, and increase cell apoptosis.

Uses

Used in Pharmaceutical Industry:
9-CIS-RETINOIC ACID is used as a therapeutic agent for the treatment of cutaneous lesions in patients with Kaposi's sarcoma (KS), a common malignancy observed in AIDS patients. As a ligand for both retinoic acid receptors (RAR) and retinoid X receptors (RXR), it plays a critical role in regulating retinoid-responsive pathways, leading to increased cell apoptosis and inhibition of cellular proliferation in experimental models of human cancer.
Used in Topical Treatment:
9-CIS-RETINOIC ACID is used as a topical treatment in the form of a 0.1% gel formulation under the brand name Panretin (Ligand). In an international phase III trial, 42% of 82 patients treated with this formulation experienced complete or partial responses, compared to 7% for controls. This makes Alitretinoin the first topical therapy for KS and a promising new option for its traditional management.
Used in Research and Development:
As a biologically active ligand for RAR and RXR subfamilies, 9-CIS-RETINOIC ACID is also utilized in research and development for understanding the molecular mechanisms underlying various diseases and the potential development of new therapeutic strategies targeting these pathways.

Indications

Alitretinoin (Panretin) is a naturally occurring endogenous retinoid that binds to and activates all known retinoid receptors (both RARs and RXRs). It is approved for the topical treatment of cutaneous lesions of Kaposi’s sarcoma. Most patients have local irritation while using alitretinoin gel; however, the irritation rarely necessitates discontinuation of therapy.

Biochem/physiol Actions

Ligand for both the retinoic acid receptor (RAR) and the retinoid X receptor (RXR) that act as transcription factors to regulate the growth and differentiation of normal and malignant cells.

Check Digit Verification of cas no

The CAS Registry Mumber 5300-03-8 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,3,0 and 0 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 5300-03:
(6*5)+(5*3)+(4*0)+(3*0)+(2*0)+(1*3)=48
48 % 10 = 8
So 5300-03-8 is a valid CAS Registry Number.
InChI:InChI=1/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+

5300-03-8 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma

  • (R4643)  9-cis-Retinoicacid  ≥98% (HPLC)

  • 5300-03-8

  • R4643-1MG

  • 792.09CNY

  • Detail

5300-03-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 9-cis-retinoic acid

1.2 Other means of identification

Product number -
Other names 9-cis-Tretinoin

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:5300-03-8 SDS

5300-03-8Relevant articles and documents

Catalytic synthesis of 9-cis-retinoids: Mechanistic insights

Kahremany, Shirin,Kubas, Adam,Tochtrop, Gregory P.,Palczewski, Krzysztof

supporting information, p. 10581 - 10595 (2019/07/22)

The regioselective Z-isomerization of thermodynamically stable all-trans retinoids remains challenging, and ultimately limits the availability of much needed therapeutics for the treatment of human diseases. We present here a novel, straightforward approach for the catalytic Z-isomerization of retinoids using conventional heat treatment or microwave irradiation. A screen of 20 transition metal-based catalysts identified an optimal approach for the regioselective production of Z-retinoids. The most effective catalytic system was comprised of a palladium complex with labile ligands. Several mechanistic studies, including isotopic H/D exchange and state-of-the-art quantum chemical calculations using coupled cluster methods indicate that the isomerization is initiated by catalyst dimerization followed by the formation of a cyclic, six-membered chloropalladate catalyst-substrate adduct, which eventually opens to produce the desired Z-isomer. The synthetic development described here, combined with thorough mechanistic analysis of the underlying chemistry, highlights the use of readily available transition metal-based catalysts in straightforward formats for gram-scale drug synthesis.

Stereospecific synthesis process for tretinoin compounds

-

Page/Page column 10; 11, (2014/09/29)

A stereospecific synthesis process for tretinoin compounds comprises the following steps: using substituted triphenyl phosphine salt and β-formyl crotonic acid as raw material to carry out WITTIG reaction under the action of alkali; then adjusting the pH of the reaction liquid to 5-10; adding palladium compound or rhodium compound to carry out isomerization directly and obtain tretinoin compounds with desired configuration. The product yield of the process is high and the intermediate product in the reaction dose not need to be separated. The process is easy to operate and can save the production cost and as well is suitable for industrial production.

A sensitive and specific method for measurement of multiple retinoids in human serum with UHPLC-MS/MS

Arnold, Samuel L. M.,Amory, John K.,Walsh, Thomas J.,Isoherranen, Nina

experimental part, p. 587 - 598 (2012/05/31)

Retinol (vitamin A) circulates at 1-4 μM concentration and is easily measured in serum. However, retinol is biologically inactive. Its metabolite, retinoic acid (RA), is believed to be responsible for biological effects of vitamin A, and hence the measurement of retinol concentrations is of limited value. A UHPLC-MS/MS method using isotope-labeled internal standards was developed and validated for quantitative analysis of endogenous RA isomers and metabolites. The method was used to measure retinoids in serum samples from 20 healthy men. In the fed state, the measured concentrations were 3.1 ± 0.2 nM for at RA, 0.1 ± 0.02 nM for 9-cisRA, 5.3 ± 1.3 nM for 13-cisRA, 0.4 ± 0.4 nM for 9,13-dicisRA, and 17.2 ± 6.8 nM for 4oxo-13-cisRA. The concentrations of the retinoids were not significantly different when measured after an overnight fast (3.0 ± 0.1 nM for atRA, 0.09 ± 0.01nM for 9-cisRA, 3.9 ± 0.2 nM for 13-cisRA, 0.3 ± 0.1 nM for 9,13-dicisRA, and 11.9 ± 1.6 nM for 4oxo-13-cisRA). 11-cisRA and 4OH-RA were not detected in human serum. The high sensitivity of the MS/MS method combined with the UHPLC separation power allowed detection of endogenous 9-cis RA and 4oxo-atRA for the first time in human serum. Copyright

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 5300-03-8